MX347901B - Uso y composicion para tratar la demencia. - Google Patents

Uso y composicion para tratar la demencia.

Info

Publication number
MX347901B
MX347901B MX2014004035A MX2014004035A MX347901B MX 347901 B MX347901 B MX 347901B MX 2014004035 A MX2014004035 A MX 2014004035A MX 2014004035 A MX2014004035 A MX 2014004035A MX 347901 B MX347901 B MX 347901B
Authority
MX
Mexico
Prior art keywords
achei
selective
patient
anticholinergic agent
type dementia
Prior art date
Application number
MX2014004035A
Other languages
English (en)
Inventor
Thomas N Chase
Kathleen E Clarence-Smith
Original Assignee
Chase Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347901(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chase Pharmaceuticals Corp filed Critical Chase Pharmaceuticals Corp
Publication of MX347901B publication Critical patent/MX347901B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un método para incrementar la dosis máxima tolerada y de esta manera la eficacia de un inhibidor de acetilcolina esterasa (AChEI) en un paciente que sufre de demencia del tipo Alzheimer al disminuir los efectos adversos concomitantes por medio de la administración del AChEI en combinación con un agente anticolinérgico, periférico, no selectivo, por lo cual se logra una inhibición mejorada de acetilcolina esterasa en el CNS del paciente y el alivio de los síntomas de demencia del tipo Alzheimer en el paciente se mejora por lo cual a un grado mayor. También se describe el uso de un agente anticolinérgico, periférico, no selectivo (nsPAChA) para la preparación de una composición farmacéutica para incrementar la dosis máxima tolerada y de esta manera la eficacia de un inhibidor de acetilcolina esterasa (AChEI) en un paciente que sufre de demencia del tipo Alzheimer y composiciones farmacéuticas que comprenden un agente anticolinérgico periférico, no selectivo de la fórmula II como se ilustra en la descripción y un inhibidor de acetilcolina esterasa.
MX2014004035A 2008-03-27 2009-03-17 Uso y composicion para tratar la demencia. MX347901B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08005750 2008-03-27
PCT/US2009/001662 WO2009120277A1 (en) 2008-03-27 2009-03-17 Use and composition for treating dementia

Publications (1)

Publication Number Publication Date
MX347901B true MX347901B (es) 2017-05-18

Family

ID=39535697

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2010010460A MX2010010460A (es) 2008-03-27 2009-03-17 Uso y composicion para tratar la demencia.
MX2014004035A MX347901B (es) 2008-03-27 2009-03-17 Uso y composicion para tratar la demencia.
MX2013009019A MX344177B (es) 2008-03-27 2009-03-17 Uso y composicion para tratar la demencia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010010460A MX2010010460A (es) 2008-03-27 2009-03-17 Uso y composicion para tratar la demencia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013009019A MX344177B (es) 2008-03-27 2009-03-17 Uso y composicion para tratar la demencia.

Country Status (10)

Country Link
US (5) US8404701B2 (es)
EP (3) EP4088717A1 (es)
JP (3) JP5647099B2 (es)
AU (1) AU2009229372C1 (es)
CA (1) CA2718411C (es)
DK (1) DK2271218T3 (es)
ES (1) ES2634421T3 (es)
MX (3) MX2010010460A (es)
PL (1) PL2271218T3 (es)
WO (1) WO2009120277A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969402B2 (en) 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
US8877768B2 (en) 2009-09-18 2014-11-04 Chase Pharmaceuticals Corporation Method and composition for treating alzheimer-type dementia
CA2718411C (en) 2008-03-27 2016-02-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
CA2804215C (en) 2009-07-22 2019-10-01 Eric Elenko Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
JP2011213606A (ja) * 2010-03-31 2011-10-27 Sawai Pharmaceutical Co Ltd ドネペジルを含有する固形製剤の製造方法
JP2011213695A (ja) * 2010-04-02 2011-10-27 Taisho Pharm Ind Ltd ドネペジル塩酸塩含有口腔内速崩壊錠
BR112015004902A2 (pt) * 2012-09-05 2017-07-04 Chase Pharmaceuticals Corp métodos e composição neutroprotetores anticolinérgicos
CA2973372A1 (en) 2015-01-09 2016-07-14 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
CA2978214A1 (en) * 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination
US10307409B2 (en) * 2015-03-06 2019-06-04 Chase Pharmaceuticals Corporation Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
US10596139B2 (en) 2015-03-06 2020-03-24 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
CN108024967B (zh) 2015-06-15 2021-12-21 库姆制药有限责任公司 格隆铵脂肪酸盐及其制备方法
EP3324966A4 (en) * 2015-07-20 2019-04-10 Chase Pharmaceuticals Corporation MUSCARINIC COMBINATION OF A SELECTIVE M2 RECEPTOR ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR THE TREATMENT OF HYPOCHOLINERGIC DISORDERS
EP3347011A4 (en) 2015-09-11 2019-06-19 Chase Pharmaceuticals Corporation MUSCARIN COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGEN DISORDERS OF THE CENTRAL NERVOUS SYSTEM
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
US10479706B2 (en) * 2016-06-03 2019-11-19 Katz Water Tech, Llc Apparatus, method and system for desalinating water
US20190269627A1 (en) 2016-10-28 2019-09-05 Chase Pharmaceuticals Corporation Memantine combinations and use
CA3096557A1 (en) * 2018-04-17 2019-10-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of solifenacin
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
WO2022058940A1 (ko) * 2020-09-21 2022-03-24 닥터레이몬드 랩(주) 인지 능력 개선 또는 기억력 증진용 의약 조성물
US12109202B2 (en) 2021-01-29 2024-10-08 Qaam Pharmaceuticals, Llc Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB795758A (en) 1955-08-22 1958-05-28 Pfizer & Co C Amino esters and the preparation thereof
US3480626A (en) 1967-05-18 1969-11-25 Chem Fab Dr R Pfleger Certain azoniaspironortropine derivatives
GB1204580A (en) 1968-10-05 1970-09-09 Aspro Nicholas Ltd Pharmaceutical dosage forms
US3576388A (en) 1968-12-05 1971-04-27 Stauffer Wacker Silicone Corp Electrical cable
DD106643A1 (es) 1973-07-12 1974-06-20
US4965074A (en) 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US4798841A (en) 1987-03-31 1989-01-17 Warner-Lambert Company Tetrahydropyridine oxime cholinergic agents and method of treatment
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
US4937239A (en) 1989-02-13 1990-06-26 Warner-Lambert Company Azabicycloalkane oxime & azabicycloalkene oxime muscarinic agents
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
GB9612710D0 (en) 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
ES2255170T3 (es) 1997-07-09 2006-06-16 Axonyx Inhibidores de butirilcolinesterasa altamente selectivos para el tratamiento y diagnostico de demencias y de la enfermedad de alzheimer.
EP0976404A3 (en) 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
CA2310926C (en) 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU2002253929A1 (en) * 2001-02-08 2002-09-24 Schering Corporation Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7427280B2 (en) * 2002-09-06 2008-09-23 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues
US6974820B2 (en) 2002-11-06 2005-12-13 Bridge Pharma, Inc. Methods for treating urinary incontinence and other disorders using trospium
CN1520818A (zh) 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
US8299062B2 (en) 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
ATE443701T1 (de) 2004-01-16 2009-10-15 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
AU2005215136A1 (en) 2004-02-20 2005-09-01 Novartis Ag DPP-IV inhibitors for treating neurodegeneration and cognitive disorders
AR051950A1 (es) 2004-11-10 2007-02-21 Osmotica Pharmaceutical Argent Comprimido multicapa con capas que se separan
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
US20070004766A1 (en) 2005-07-01 2007-01-04 Aberg A K G Methods for relaxation of smooth muscle contractions using Trospium
US20070224259A1 (en) 2005-09-21 2007-09-27 Gupta Anil K Anti-inflammatory pharmaceutical composition
SI1933809T1 (sl) 2005-10-11 2012-08-31 Yissum Res Dev Co Sestavki za mazalno dajanje
BRPI0710470A2 (pt) * 2006-04-21 2011-08-16 Wyeth Corp métodos para preparar seletivamente um aminoálcool quiral e uma sulfonamida quiral
JP2010503669A (ja) * 2006-09-12 2010-02-04 アドラー コーポレーション 認知機能の強化のためのｎ含有スピロ化合物の使用
US20080090808A1 (en) 2006-10-17 2008-04-17 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
US8097633B2 (en) * 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
CA2718411C (en) * 2008-03-27 2016-02-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
US8877768B2 (en) * 2009-09-18 2014-11-04 Chase Pharmaceuticals Corporation Method and composition for treating alzheimer-type dementia

Also Published As

Publication number Publication date
US20150224096A1 (en) 2015-08-13
AU2009229372B2 (en) 2014-09-25
CA2718411C (en) 2016-02-16
EP2271218A4 (en) 2011-05-18
EP4088717A1 (en) 2022-11-16
JP5647099B2 (ja) 2014-12-24
JP2011518776A (ja) 2011-06-30
US20110021503A1 (en) 2011-01-27
AU2009229372A1 (en) 2009-10-01
JP6427522B2 (ja) 2018-11-21
WO2009120277A1 (en) 2009-10-01
PL2271218T3 (pl) 2017-10-31
US20130158012A1 (en) 2013-06-20
JP2016179980A (ja) 2016-10-13
EP2271218B1 (en) 2017-05-24
CA2718411A1 (en) 2009-10-01
EP3178477A1 (en) 2017-06-14
ES2634421T3 (es) 2017-09-27
US20190091214A1 (en) 2019-03-28
US20140275036A1 (en) 2014-09-18
JP2014114295A (ja) 2014-06-26
US8404701B2 (en) 2013-03-26
MX344177B (es) 2016-12-08
EP2271218A1 (en) 2011-01-12
AU2009229372C1 (en) 2017-02-02
US9044472B2 (en) 2015-06-02
MX2010010460A (es) 2010-12-15
DK2271218T3 (en) 2017-09-11

Similar Documents

Publication Publication Date Title
MX344177B (es) Uso y composicion para tratar la demencia.
CA2773592C (en) Method and composition for treating alzheimer-type dementia
NZ619076A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
MX2020002113A (es) Composicion neuroprotectora anticolinergica y metodos.
MX2009003727A (es) Acidos y esteres boronicos como inhibidores de amida hidrolasa de acido graso.
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
EA201170061A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
EA201200390A1 (ru) Макроциклические ингибиторы сериновых протеаз гепатита с
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
WO2007143607A3 (en) Method of treating atrophic vaginitis
IN2012DN01233A (es)
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2007128086A3 (en) Novel viral replication inhibitor
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
MX2012014301A (es) Inhibidores macrociclicos de serina proteasa de hepatitis c.
MD20140044A2 (ro) 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
NI201100024A (es) [ 4 - ( 5 - aminometil - 2 - fluoro - fenil ) - piperidin -1- il ] - [ 17-fluor0 - 1 - (2 - metoxi - etil ) - 4 - trifluorometoxi - 1h - indol - 3 - il] - metanona como un inhibidor de la triptasa de mastocitos.
NO20084826L (no) Ny administrasjonsform av racecadotril
EP2417115A4 (en) FATTY ACID AMIDE HYDROLASE INHIBITORS
BR112012024708A2 (pt) composição de compostos orgânicos
EA201001100A1 (ru) Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
WO2009148600A3 (en) Deuterated lysine-based compounds